Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin

British Journal of Clinical Pharmacology

Volumn 70, Issue 6, 2010, Pages 815-824

  Ma, Guangli ^a   Friberg, Lena E ^a   Movin Osswald, Gunilla ^b   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Agonist antagonist interaction model; Circadian rhythm; Pool model; Prolactin; Remoxipride; Tolerance

Indexed keywords

PROLACTIN; REMOXIPRIDE;

ADULT; AGONIST ANTAGONIST INTERACTION MODEL; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INFUSION; DRUG RECEPTOR BINDING; FEEDBACK SYSTEM; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROCESS MODEL; PROLACTIN RELEASE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD SPECIMEN COLLECTION; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG TOLERANCE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROLACTIN; REMOXIPRIDE;

EID: 78349290100     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03758.x     Document Type: Article

References (25)

1. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999; 35(Suppl.):S67-73.
2. Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 1995; 274: 921-7.
3. Bagli M, Suverkrup R, Quadflieg R, Hoflich G, Kasper S, Moller HJ, Langer M, Barlage U, Rao ML. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther 1999; 291: 547-54.
4. Friberg LE, Vermeulen AM, Petersson KJ, Karlsson MO. An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 2009; 85: 409-17.
5. Movin-Osswald G, Hammarlund-Udenaes M, Von Bahr C, Eneroth P, Walton-Bowen K. Influence of the dosing interval on prolactin release after remoxipride. Br J Clin Pharmacol 1995; 39: 503-10.
6. Francheteau P, Steimer JL, Dubray C, Lavene D. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922. J Pharmacokinet Biopharm 1991; 19: 287-309.
7. Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. Twenty-four-hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. J Clin Endocrinol Metab 1990; 71: 1616-23.
8. Jonsson EN, Karlsson MO. Xpose- an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
9. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit- a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57.
10. Wilkins J, Karlsson MO, Jonsson E. Patterns and power for the visual predictive check. PAGE 2006; Abstr 1028.15.
11. Frantz AG. Prolactin. N Engl J Med 1978; 298: 201-7.
12. Wheeler MJ. Infertility. In: The Immunoassay Handbook, 3rd edn. ed. Wild D. New York: Elsevier Ltd, 2005; 571.
13. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57-73.
14. Leysen JE, Schotte A, Janssen PMF, Gommeren W, Van Gompel P, Lesage AS, De Backer MD, Luyten WHML, Amlaiky N, Megens AAHP. Interaction of new antipsychotics with neurotransmitter receptors in vitro and in vivo: pharmacological to therapeutic significance. In: Fog R, Gerlach J, Hemningsen R, editors. Schizophrenia, an integrated view. Munskgard, Copenhagen. Denmark: Alfred Benson Symposium 1995; 38: 344-56.
15. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994; 55: Suppl:5-12.
16. Mohell N, Sällemark M, Rosqvist S, Malmberg Å, Högberg T, Jackson DM. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur J Pharmacol 1993; 238: 121-5.
17. Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992; 41: 494-508.
18. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002; 162: 42-9.
19. Karlsson P, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr Res 2006; 81: 85-6.
20. Farde L, Von Bahr C. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand Suppl 1990; 358: 67-71.
21. Movin-Osswald G, Hammarlund-Udenaes M. Remoxipride: pharmacokinetics and effect on plasma prolactin. Br J Clin Pharmacol 1991; 32: 355-60.
22. Vermeulen A, Piotrovsky V, Ludwig EA. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn 2007; 34: 183-206.
23. Cooper DS, Ridgway EC, Kliman B, Kjellberg RN, Maloof F. Metabolic clearance and production rates of prolactin in man. J Clin Invest 1979; 64: 1669-80.
24. Lange T, Dimitrov S, Fehm HL, Westermann J, Born J. Shift of monocyte function toward cellular immunity during sleep. Arch Intern Med 2006; 166: 1695-700.
25. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-631.